Cargando…
Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer
Lung cancer is difficult to treat with a poor prognosis and a five year survival of 15%. Current molecularly targeted therapies are initially effective in non-small cell lung cancer (NSCLC) patients; however, they are plagued with difficulties including induced resistance and small therapeutically r...
Autores principales: | Chhabra, Gagan, Eggert, Ashley, Puri, Neelu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894332/ https://www.ncbi.nlm.nih.gov/pubmed/27280107 |
Ejemplares similares
-
Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
por: Schrank, Zachary, et al.
Publicado: (2018) -
Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Botting, Gregory M., et al.
Publicado: (2015) -
Resistance to Molecularly Targeted Therapies in Melanoma
por: Patel, Meet, et al.
Publicado: (2021) -
Oligonucleotides and microRNAs Targeting Telomerase Subunits in Cancer Therapy
por: Eckburg, Adam, et al.
Publicado: (2020) -
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
por: Puri, Neelu, et al.
Publicado: (2008)